(Q73599559)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

G W Moe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J L Rouleau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

L Charbonneau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

G Proulx

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J M Arnold

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

C Hall

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J de Champlain

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Barr

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P Sirois

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M Packer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 April 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

587-595

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure.

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Effect of flosequinan on exercise capacity and symptoms in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Chronic vasodilator therapy with flosequinan in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Flosequinan: a vasodilator with positive inotropic activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Neurohormonal interactions and adaptations in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

The plasma concentration of N-terminal proatrial natriuretic factor ANF(1-98) is related to prognosis in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990035-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(00)90035-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740139%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference